Canada Approves Second Generic Version of Ozempic by Apotex

Key Facts

Health Canada has officially authorized Apotex to produce and market a generic version of semaglutide, the active ingredient in the blockbuster drug Ozempic. This authorization marks the second generic alternative to Novo Nordisk's diabetes treatment to be approved in the Canadian market. The introduction of generic competition is expected to drive down costs and improve the supply chain for patients requiring semaglutide. For Novo Nordisk, the move represents a strategic challenge as it faces potential pressure on market share and pricing power in a key territory. Global demand for these treatments remains exceptionally high, making the entry of generic players a significant development for the industry. Analysts suggest that increased competition in this segment could impact the long-term margins of original patent holders. This regulatory milestone underscores Canada's commitment to expanding access to essential pharmaceutical treatments.